i think that's right ,Phil.

I found this on AI

Yes, when considering salvage radiation therapy (SRT) with androgen deprivation therapy (ADT) for recurrent prostate cancer, a 5-year freedom from biochemical progression rate as high as 87.4% has been reported in a phase 3 randomized controlled trial. This study, the SPPORT trial, evaluated SRT to the prostatic bed and pelvic lymph nodes, combined with a short course of ADT. This was the experimental arm in the study, and it showed a higher freedom from progression rate compared to SRT to the prostatic bed with ADT (81.3%) or SRT alone (70.9%). The SPPORT trial indicated that SRT plus ADT offered a benefit in progression-free survival.